Arkolith/Insider Trading/QNCX/Form 4

Hannah Brendan

CHIEF BUSINESS OFFICER AND COOQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Aug 21, 2024
Net Buying
Open-Market Buys
$24K
Open-Market Sells
$0
Net Open-Market Flow
$24K
Transactions
6
6 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 21, 2024Buy(P)24K$0.63$15K297K
Aug 21, 2024Buy(P)2K$0.61$1K268K
Aug 21, 2024Buy(P)5K$0.62$3K273K
Aug 20, 2024Buy(P)3K$0.61$2K262K
Aug 20, 2024Buy(P)3K$0.60$2K266K
Aug 19, 2024Buy(P)2K$0.58$1K260K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-021869) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML